Article
Hematology
Se Young Han, Krzysztof Mrozek, Jenna Voutsinas, Qian Wu, Elizabeth A. Morgan, Hanne Vestergaard, Robert Ohgami, Philip M. Kluin, Thomas Kielsgaard Kristensen, Sheeja Pullarkat, Michael Boe Moller, Ana-Iris Schiefer, Linda B. Baughn, Young Kim, David Czuchlewski, Jacobien R. Hilberink, Hans-Peter Horny, Tracy George, Michelle Dolan, Nam K. Ku, Cecilia Arana Yi, Vinod Pullarkat, Jessica Kohlschmidt, Amandeep Salhotra, Lori Soma, Clara D. Bloomfield, Dong Chen, Wolfgang R. Sperr, Guido Marcucci, Christina Cho, Cem Akin, Jason Gotlib, Sigurd Broesby-Olsen, Melissa Larson, Michael A. Linden, H. Joachim Deeg, Gregor Hoermann, Miguel-Angel Perales, Jason L. Hornick, Mark R. Litzow, Ryotaro Nakamura, Daniel Weisdorf, Gautam Borthakur, Gerwin Huls, Peter Valent, Celalettin Ustun, Cecilia C. S. Yeung
Summary: Patients with core-binding factor (CBF) acute myeloid leukemia (AML) caused by t(8; 21) or inv(16) have higher complete remission rates and longer survival compared to patients with other subtypes of AML. However, about 40% of patients still experience relapse, with differences in outcomes between inv(16) and t(8;21) patients. Various cytogenetic abnormalities, such as trisomies and deletions, were associated with different clinical outcomes in these patients.
Article
Multidisciplinary Sciences
Lianjun Zhang, Le Xuan Truong Nguyen, Ying-Chieh Chen, Dijiong Wu, Guerry J. Cook, Dinh Hoa Hoang, Casey J. Brewer, Xin He, Haojie Dong, Shu Li, Man Li, Dandan Zhao, Jing Qi, Wei-Kai Hua, Qi Cai, Emily Carnahan, Wei Chen, Xiwei Wu, Piotr Swiderski, Russell C. Rockne, Marcin Kortylewski, Ling Li, Bin Zhang, Guido Marcucci, Ya-Huei Kuo
Summary: The study elucidates that aberrant expression of miR-126 in inv(16) AML is directly induced by the CBFB-MYH11 fusion gene, promoting AML development and maintaining leukemia stem cells. This highlights miR-126 as a therapeutic target for inv(16) AML patients.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Jochen Greiner, Elliott Brown, Lars Bullinger, Robert K. Hills, Vanessa Morris, Hartmut Doehner, Ken I. Mills, Barbara-ann Guinn
Summary: This study found that BIRC5 expression plays a role in the survival of AML patients, with above median levels associated with improved overall survival but not reaching statistical significance. Adjusted analyses showed a beneficial effect of high BIRC5 levels on overall survival. Additionally, decreased BIRC5 expression was associated with better clinical outcome.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Kun-yin Qiu, Xiong-yu Liao, Yang Li, Ke Huang, Hong-gui Xu, Jian-pei Fang, Dun-hua Zhou
Summary: This study compared the outcome and prognostic factors between inv(16) and t(8;21) in AML. It was found that patients with t(8;21) had lower overall survival and lower relapse rate. Additionally, pediatric AML patients receiving more cytarabine courses had lower relapse rate. For inv(16) patients not receiving GO treatment, the overall survival was lower and the relapse rate was higher compared to t(8;21) patients. However, inv(16) and t(8;21) patients receiving GO treatment had comparable outcomes.
Article
Oncology
Ana Catarina Menezes, Rachel Jones, Alina Shrestha, Rachael Nicholson, Adam Leckenby, Aleksandra Azevedo, Sara Davies, Sarah Baker, Amanda F. Gilkes, Richard L. Darley, Alex Tonks
Summary: The role of RUNX3 in normal myeloid development and leukemia, particularly acute myeloid leukemia (AML), is investigated. The study shows that increased expression of RUNX3 in AML can contribute to the developmental arrest characteristic of the disease. Overexpression of RUNX3 inhibits myeloid differentiation and proliferation in human hematopoietic stem and progenitor cells (HSPC), while RUNX3 knockdown does not impact myeloid growth and development. These findings suggest that dysregulation of RUNX3 may play an important role in the pathogenesis of AML.
Review
Hematology
Takako Yokomizo-Nakano, Goro Sashida
Summary: RUNX3, known as a tumor suppressor in various cancers, has been found to have an oncogenic function in myeloid malignancies. Although deletions and loss-of-function mutations in RUNX3 are rare in hematopoietic malignancies, its overexpression can lead to malignant transformation.
EXPERIMENTAL HEMATOLOGY
(2021)
Editorial Material
Medicine, General & Internal
Ana Vega Gonzalez de Vinaspre, Carlos De Miguel Sanchez, Diego Robles De Castro, Veronica Roldan Galiacho, Arantza Mendizabal Abad, Jose Maria Guinea De Castro
Summary: Faggot cells are rarely seen in nonacute promyelocytic leukemia, and even rarer in mature granulocytic cells. When pre-eosinophilic granulation and faggot neutrophils are observed, the possibility of inv(16) should be ruled out.
CLINICAL CASE REPORTS
(2021)
Article
Immunology
Nan Xu, Kai Sun, Ya-Zhe Wang, Wen-Min Chen, Jun Wang, Ling-Di Li, Xu Wang, Yue Hao, Yan Chang, Yan-Rong Liu, Xiao-Jun Huang, Ya-Zhen Qin
Summary: The transcript level of IL7R in bone marrow at diagnosis is predictive of relapse risk in t(8;21) AML, and this may be attributed to differences in the quantity, status, and function of T cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Ran Li, Xiaolu Wu, Kai Xue, Dandan Feng, Jianyong Li, Junmin Li
Summary: This study reveals the high expression of ALKBH5 in t (8;21) AML patients and the silencing of ALKBH5 inhibits cell proliferation and promotes apoptosis. It is further found that ALKBH5 can demethylate ITPA mRNA and increase its stability, leading to enhanced ITPA expression. Additionally, the transcription factor TCF15, specifically expressed in leukemia stem/initiating cells (LSCs/LICs), is responsible for the dysregulated expression of ALKBH5 in t (8;21) AML.
BIOMARKER RESEARCH
(2023)
Article
Biotechnology & Applied Microbiology
Kuan-Wei Su, Da-Liang Ou, Yu-Hsuan Fu, Hwei-Fang Tien, Hsin-An Hou, Liang-In Lin
Summary: Cabozantinib, an orally available multi-target tyrosine kinase inhibitor, showed potential therapeutic effects in an AML subtype characterized by t(8;21) and KIT mutation. It exerted cytotoxicity in Kasumi-1 cells, inhibited KIT phosphorylation and downstream signals, disrupted AML1-ETO fusion protein synthesis, suppressed tumorigenesis in a mouse model, and downregulated mTOR-mediated signaling pathways. Further clinical trials are warranted to evaluate its efficacy in AML treatment.
CANCER GENE THERAPY
(2022)
Article
Biology
Wenyi Zhang, Hainan Wang, Peilei Zhang, Hongliang Li, Xiaoli Ma, Hongxing Liu
Summary: The 16p13.1q22 inversion in acute myeloid leukemia (AML) leads to various types of CBF beta/MYH11 fusion genes, with type I being rare. A patient with this inversion showed atypical morphological analysis, but achieved hematological and genetic remission. Constant positivity of the CBF beta/MYH11 fusion gene was observed, and the presence of non-type A fusions may impact prognosis. Further research is crucial to understand the biological and prognostic significance of these genetic abnormalities.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
(2021)
Article
Hematology
Bon Q. Trinh, Simone Ummarino, Yanzhou Zhang, Alexander K. Ebralidze, Mahmoud A. Bassal, Tuan M. Nguyen, Gerwin Heller, Rory Coffey, Danielle E. Tenen, Emiel van der Kouwe, Emiliano Fabiani, Carmelo Gurnari, Chan-Shuo Wu, Vladimir Espinosa Angarica, Henry Yang, Sisi Chen, Hong Zhang, Abby R. Thurm, Francisco Marchi, Elena Levantini, Philipp B. Staber, Pu Zhang, Maria Teresa Voso, Pier Paolo Pandolfi, Susumu S. Kobayashi, Li Chai, Annalisa Di Ruscio, Daniel G. Tenen
Summary: This study identifies a myeloid-specific lncRNA, LOUP, as a transcriptional inducer of PU.1 through recruiting RUNX1, forming an active chromatin loop. In AML, the oncogenic fusion protein RUNX1-ETO limits chromatin accessibility at the LOUP locus, leading to suppression of LOUP and PU.1 expression.
Article
Medical Laboratory Technology
Zhaohua Zhang, Piaoyan Zhang, Suipeng Chen, Xiao Feng, Ruqing Yang, Yongshi Zhao, Xinyi Zhou, Qianru Jin, Chuan Sun, Qian Li
Summary: This study reviewed 58 cases of AML in children and adults with t(8;21)(q22;q22) translocation, and found 5 variant translocation cases. Patients with AML with t(8;21) variant translocation have different prognoses and require further study.
CLINICAL LABORATORY
(2023)
Article
Medical Laboratory Technology
Zhaohua Zhang, Piaoyan Zhang, Suipeng Chen, Xiao Feng, Ruqing Yang, Yongshi Zhao, Xinyi Zhou, Qianru Jin, Chuan Sun, Qian Li
Summary: This study reviewed 58 cases of children and adults with AML and t(8;21) translocation. It observed variant translocation cases and analyzed the prognostic factors. The results suggest that patients with AML and t(8;21) variant translocation have different prognoses and further study is needed.
CLINICAL LABORATORY
(2022)
Article
Oncology
Shujiao He, Yan Li, Xuanren Shi, Lei Wang, Diya Cai, Jingfeng Zhou, Li Yu
Summary: This study compared the DNA methylation landscape of t(8;21) AML patients with that of non-t(8;21) AML patients, and identified the mechanisms underlying the response to decitabine treatment. It was found that t(8;21) AML patients achieved better clinical outcomes with decitabine-based therapy, which was associated with specific methylation regions and gene expression regulation. LIN7A was identified as a decitabine-sensitive gene in t(8;21) AML patients, and its expression level was closely related to treatment response and prognosis.
CLINICAL EPIGENETICS
(2023)
Letter
Oncology
Wilson Y. K. Chan, Pamela P. W. Lee, Daniel K. L. Cheuk, Eva W. M. Yeung, Kenneth C. W. Wong, C. K. Li, Godfrey C. F. Chan, Wing Leung
PEDIATRIC BLOOD & CANCER
(2023)
Article
Hematology
Fanny Delehaye, Jeremie Rouger, David Brossier, Meinolf Suttorp, Adalet Meral Gunes, Petr Sedlacek, Birgitta Versluys, Chi Kong Li, Krzysztof Kalwak, Birgitte Lausen, Culic Srdjana, Michael Dworzak, Andrea Hraskova, Barbara De Moerloose, Farah Roula, Anais Briant, Jean-Jacques Parienti, Frederic Millot
Summary: The clinical presentation of chronic myeloid leukemia (CML) differs in children compared to adults. Anemia at diagnosis is frequent in pediatric CML and may be considered as a prognostic factor. Moderate and severe anemia at diagnosis in children with CML is significantly associated with younger age, asthenia, splenomegaly, increased leukocyte and basophil counts, delayed major and deep molecular responses, and more frequent failure of imatinib treatment. However, the hemoglobin level is not significantly associated with survival.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Chung-tin Ma, Ho Wing Chou, Teddy Tai-ning Lam, Yan Tung Tung, Yat Wing Lai, Lai-ka Lee, Vivian Wing-yan Lee, Nelson Chun-yiu Yeung, Alex Wing-Kwan Leung, Smita Bhatia, Chi Kong Li, Yin Ting Cheung
Summary: This study evaluated the short-term effectiveness of a personalized survivorship care plan (SCP) in improving cancer-related literacy among childhood cancer survivors. It found that the provision of a personalized SCP showed preliminary effectiveness in improving survivors' understanding of their treatment-related late effects (LEs).
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Yin Ting Cheung, Chung Tin Ma, Michael Can Heng Li, Keary Rui Zhou, Herbert Ho Fung Loong, Agnes Sui Yin Chan, Kwok Chuen Wong, Chi Kong Li
Summary: Young survivors of bone tumors and soft-tissue sarcoma are at risk of cognitive impairment. Physical inactivity, smoking, and long working hours are associated with worse attention and executive function among survivors. Chronic health conditions coupled with continued physical inactivity may exacerbate cognitive dysfunction.
Article
Pharmacology & Pharmacy
Xiaoqing Fan, Wojciech Krzyzanski, Dongyang Liu, Raymond S. M. Wong, Xiaoyu Yan
Summary: Recombinant human erythropoietin (rHuEPO) is an effective drug for anemia treatment in patients with chronic kidney disease. However, EPO-resistance is a significant issue. Combining rHuEPO with romiplostim, a thrombopoietin receptor agonist, can overcome EPO-resistance.
Article
Hematology
Kun-yin Qiu, Jia-yi Wang, Li-bin Huang, Chang-gang Li, Lu-hong Xu, Ri-yang Liu, Hui-qin Chen, Yong-sheng Ruan, Zi-jun Zhen, Chi-kong Li, Jian-pei Fang
Summary: The efficacy and safety of adding vincristine and dexamethasone pulses to maintenance therapy for childhood acute lymphoblastic leukemia (ALL) remain uncertain, according to a randomized, open-label, multicenter, phase III clinical trial conducted in Guangdong Province, China.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Honghong Zhang, Yang Wan, Hongsheng Wang, Jiaoyang Cai, Jie Yu, Shaoyan Hu, Yongjun Fang, Ju Gao, Hua Jiang, Minghua Yang, Changda Liang, Runming Jin, Xin Tian, Xiuli Ju, Qun Hu, Hui Jiang, Zhifan Li, Ningling Wang, Lirong Sun, Alex W. K. Leung, Xuedong Wu, Xiaowen Qian, Maoxiang Qian, Chi-kong Li, Jun Yang, Jingyan Tang, Xiaofan Zhu, Shuhong Shen, Li Zhang, Ching-Hon Pui, Xiaowen Zhai
Summary: The study aims to identify prognostic factors for improving the outcome of patients with TCF3::PBX1 ALL. The presence of positive MRD and testicular leukemia are indicators for new molecular therapeutics or immunotherapy in these patients.
Article
Hematology
Yin Ting Cheung, Chung Tin Ma, Henry Hon Wai Lam, Siu Cheung Ling, Kevin Kwok, Chak Ho Li, Chung Yin Ha, Sze Fai Yip, Raymond Siu Ming Wong, Winnie Chiu Wing Chu, Chi Kong Li
Summary: This study aimed to evaluate the impact of microstructural changes and psychosocial factors on cognitive function in patients with haemophilia. The results showed that a considerable proportion of patients with haemophilia demonstrated cognitive impairment, particularly in higher-order thinking skills. Screening for cognitive deficits should be integrated into routine care, and further research is needed to examine the association between cognitive function and occupational outcomes.
Article
Oncology
Calvin Pui Lun Hoo, Alex Wing Kwan Leung, Joyce Pui Kwan Chan, Yin Ting Cheung, Frankie Wai Tsoi Cheng, Terry Tin Wai Chow, Grace Kee See Lam, Sau Yin Ha, Alan Kwok Shing Chiang, Rever Chak Ho Li, Chi Kong Li
Summary: This study retrospectively evaluated the incidence, risk factors, and clinical outcomes of avascular necrosis (AVN) among Chinese children with acute lymphoblastic leukemia (ALL). The results showed that the incidence of AVN in Chinese ALL patients was comparable to Western population studies. Age was identified as the most important risk factor, with a significantly higher incidence in adolescents above 10 years old compared to those below 10 years old. Treatment protocol, immunophenotype, and gender were not predictive of AVN.
Article
Oncology
Yin Ting Cheung, Kenneth Kin-Wah To, Rong Hua, Chui Ping Lee, Agnes Sui-Ying Chan, Chi Kong Li
Summary: This study evaluated the associations of biomarkers of inflammation with attention and neurobehavioral outcomes in survivors of childhood acute lymphoblastic leukemia (ALL). The results suggest that cancer-related inflammation may be a mechanism underlying neurobehavioral problems in pediatric ALL survivors.
FRONTIERS IN ONCOLOGY
(2023)
Letter
Health Care Sciences & Services
Esther Chui Yan Wong, Phillip Lung Wai Au-Doung, Yvonne Yuen Ling Chu, Sandy Sin Yuet Wong, Chi Kong Li, Yin Ting Cheung
BMJ SUPPORTIVE & PALLIATIVE CARE
(2023)
Article
Biology
Chi-Keung Cheng, Yuk-Lin Yung, Hoi-Yun Chan, Kam-Tong Leung, Kathy Y. Y. Chan, Alex W. K. Leung, Frankie W. T. Cheng, Chi-Kong Li, Thomas S. K. Wan, Xi Luo, Herbert-Augustus Pitts, Joyce S. S. Cheung, Natalie P. H. Chan, Margaret H. L. Ng
Summary: A genomic analysis of pediatric acute myeloid leukemia patients reveals extensive gene fusion events and mutations, providing new insights into the genetic complexities of this cancer. The study highlights the importance of understanding the genetic basis of pediatric AML for improving prognostic classification and treatment options.
COMMUNICATIONS BIOLOGY
(2023)
Article
Oncology
Chun Sing Lam, Chung Tin Ma, Michael Can Heng Li, Cho Lee Wong, Herbert Ho-Fung Loong, Alex Wing Kwan Leung, Chi Kong Li, Ho Kee Koon, Yin Ting Cheung
Summary: This study examined the use of traditional, complementary, and integrative medicines (TCIM) among adolescent and young adult cancer patients, as well as their preferences for TCIM education. The results showed that 60.2% of patients used TCIM, with the most common modalities being vitamin supplements (24.0%) and Chinese herbal medicine (22.0%). Patients used TCIM to improve general health and manage chronic symptoms. The study suggests that a tailored education program should be provided based on patients' preferences and needs, and healthcare professionals should communicate with patients and make evidence-based referrals/recommendations.
EUROPEAN JOURNAL OF ONCOLOGY NURSING
(2023)
Article
Biochemistry & Molecular Biology
Herbert Augustus Pitts, Chi-Keung Cheng, Joyce Sin Cheung, Murphy Ka-Hei Sun, Yuk-Lin Yung, Hoi-Yun Chan, Raymond S. M. Wong, Sze-Fai Yip, Ka-Ngai Lau, Wai Shan Wong, Radha Raghupathy, Natalie P. H. Chan, Margaret H. L. Ng
Summary: This study investigated the expression of serine protease inhibitor Kazal type 2 (SPINK2) in acute myeloid leukemia (AML) and its associated clinicopathological and prognostic factors. High expression of SPINK2 was found to be an adverse prognostic marker, indicating therapy resistance and relapse risk in AML. SPINK2 was also associated with specific genetic mutations and intermediate risk classification. Functionally, SPINK2 was linked to ferroptosis and immune response, affecting gene expression and sensitivity to erastin. Additionally, a potential small-molecule inhibitor of SPINK2 was identified.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Meeting Abstract
Oncology
Terry Tin Wai Chow, Wilson Yau Ki Chan, Ka Ho Chiu, Cheng Man, Hin Mark, Chak Ho Li, Ka Fai To, Chit Chow, Rex Kwok Him Au-Yeung, Elaine Tin Yan Cheung, Chi Kong Li
PEDIATRIC BLOOD & CANCER
(2023)